Northcoast Research analyst David Keiser reiterated a Buy rating on Hill-Rom (HRC) today and set a price target of $116. The company’s shares opened today at $100.48.
Keiser has an average return of 19.1% when recommending Hill-Rom.
According to TipRanks.com, Keiser is ranked #505 out of 5129 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hill-Rom with a $109.20 average price target, an 8.7% upside from current levels. In a report issued on January 25, KeyBanc also maintained a Buy rating on the stock with a $114 price target.
See today’s analyst top recommended stocks >>
Hill-Rom’s market cap is currently $6.88B and has a P/E ratio of 27.39. The company has a Price to Book ratio of 4.25.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Andreas Frank, the SVP, Pres. Front Line Care of HRC sold 7,454 shares for a total of $713,765.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following business segments: Patient Support System, Front Line Care, and Surgical Solutions.
